scholarly journals Food-Derived Natural Compounds for Pain Relief in Neuropathic Pain

2016 ◽  
Vol 2016 ◽  
pp. 1-12 ◽  
Author(s):  
Eun Yeong Lim ◽  
Yun Tai Kim
Keyword(s):  
Neuropathic Pain ◽  
Pain Relief ◽  
Immune Responses ◽  
Pain Treatment ◽  
Physical Dependence ◽  
Natural Compounds ◽  
Number Of Patients ◽  
Potential Benefits ◽  
Somatosensory Nervous System ◽  
Injury Causes

Neuropathic pain, defined as pain caused by a lesion or disease of the somatosensory nervous system, is characterized by dysesthesia, hyperalgesia, and allodynia. The number of patients with this type of pain has increased rapidly in recent years. Yet, available neuropathic pain medicines have undesired side effects, such as tolerance and physical dependence, and do not fully alleviate the pain. The mechanisms of neuropathic pain are still not fully understood. Injury causes inflammation and immune responses and changed expression and activity of receptors and ion channels in peripheral nerve terminals. Additionally, neuroinflammation is a known factor in the development and maintenance of neuropathic pain. During neuropathic pain development, the C-C motif chemokine receptor 2 (CCR2) acts as an important signaling mediator. Traditional plant treatments have been used throughout the world for treating diseases. We and others have identified food-derived compounds that alleviate neuropathic pain. Here, we review the natural compounds for neuropathic pain relief, their mechanisms of action, and the potential benefits of natural compounds with antagonistic effects on GPCRs, especially those containing CCR2, for neuropathic pain treatment.

Transcutaneous Peripheral Nerve Stimulation for the Treatment of Neuropathic Pain in the Upper Limb

2016 ◽  
Vol 21 (01) ◽  
pp. 37-43 ◽  
Author(s):  
A. Sierakowski ◽  
S.S. Jing ◽  
J. Poel ◽  
D. Elliot
Keyword(s):  
Neuropathic Pain ◽  
Pain Relief ◽  
Peripheral Nerve ◽  
Upper Limb ◽  
Nerve Stimulation ◽  
Peripheral Nerve Stimulation ◽  
Pain Severity ◽  
Intractable Pain ◽  
Paired Data ◽  
Number Of Patients

Background: A small number of patients develop intractable peripheral nerve pain following injury or surgery to the upper limb that is refractory to pharmacological treatment. This study reports our results of using transcutaneous peripheral nerve stimulation (TPNS), a non-invasive form of neuromodulation, to treat this difficult problem. Methods: Seventy-two patients were treated for intractable pain in the upper limb using this technique. Electrical current was delivered transcutaneously through a handheld probe, placed on the skin overlying the affected peripheral nerve proximal to the site of pain. Pain severity was determined before and immediately after treatment by subjective patient self-assessment using a visual analogue pain scale. Pre-post treatment changes in pain severity were analysed by Student's test for paired data. Outcome in respect of overall effectiveness of this treatment, was graded according to the maximum duration of pain relief achieved. Results: Overall, TPNS reduced pain intensity from 8.4 (SD 1.6) before treatment to 4.2 (SD 3.5) immediately after treatment, a highly significant effect ([Formula: see text]). The treatment achieved cure in 8/72 (11%) of our patients and a useful therapeutic outcome (pain relief ≥ 1 day) in 27/72 (38%). The treatment failed in 37/72 (51%). Conclusions: TPNS warrants consideration as a therapy for neuropathic pain in the upper limb after drug treatment has failed and before offering surgery or spinal root stimulation.

scholarly journals Neuropathic pain treatment between drug therapy and supplement effects

2019 ◽  
Vol 8 (11) ◽  
pp. 2573
Author(s):  
Mohammed Abdul Muttalib
Keyword(s):  
Neuropathic Pain ◽  
Pain Treatment ◽  
Medical Condition ◽  
Medical Procedure ◽  
Over The Counter ◽  
Cell Systems ◽  
Serious Illness ◽  
Topical Lidocaine ◽  
Somatosensory Nervous System ◽  
Strong Medicine

Neuropathic pain (NP) is a medical condition induced by diseases or lesions in the primary or inner cell systems that influence somatosensory nervous system buildings. Central NP, including backbone pain; multiple sclerosis, is recurrent. NP has an important impact on the life of patients and a strong economic impact on people and the society. some small neuropathy responds like a NSAID, aspirin and ibuprofen to an over-the-counter drug. More strong medicine (such as anti-depressants and serotonin-epinephrine reuptake inhibitors), anticonvulsants (pregabalin and gabapentin), and topical lidocaine-these are recognized as the most advanced neuropathical treatment-is also needed for other serious circumstances to increase ache leadership. Supplemental drugs, such as beta lipoic acid, acetyl-L-carnitine, benfotiamine, taurine and others, have been studied for neuropathic pain relieve under doctors to guarantee safe use and not bring any medicines that may interact with the dietary supplement. A medical procedure has been investigated for a neuro-lipoic pain relief. In specific, owing to the power of drug contrast with alternative products and owing to the effect of some drugs, it was considered that the drugs are (in spite of their side effects) more helpful and efficient to relieve neuropathic pain than the option, since neuropathic pain represents a serious illness and needs a more strong and effective therapy technology (particularly in severe cases).

Palmitoylethanolamide (PEA) in the treatment of neuropathic pain: a case study

2021 ◽  
pp. 026010602110196
Author(s):  
Despina Kamper
Keyword(s):  
Neuropathic Pain ◽  
Pain Relief ◽  
Underlying Mechanism ◽  
Multidisciplinary Teams ◽  
Post Herpetic Neuralgia ◽  
Appropriate Treatment ◽  
Effective Pain Relief ◽  
Somatosensory Nervous System

Background: Neuropathic pain is a condition caused by a lesion or disease of the somatosensory nervous system. It may present as debilitating pain with a sensation of burning and electric-like symptoms and is often difficult to manage effectively. Although pharmacological medications are the first line of treatment, multidisciplinary teams are sometimes required to provide appropriate treatment to improve quality of life and overall wellbeing. Aim: The aim of this study is to present a case of post herpetic neuralgia relieved successfully by the compound palmitoylethanolamide (PEA) – a natural alternative to pharmacological pain relief. Methods: We present the case of a 67 year-old male with ongoing post-herpetic neuralgia, over a 3-year period, as a result of complications from shingles (herpes zoster). Previous studies on the relationship between PEA and neuropathy were reviewed, with an attempt to discuss the possible underlying mechanism of PEA on neuropathic pain. Results: PEA demonstrated effective pain relief within 48 hours at an administered daily dose of 900 mg (10 mg/kg). Conclusions: PEA may offer a valid nutraceutical treatment for practitioners.

scholarly journals Neuropathic Pain and Rehabilitation: A Systematic Review of International Guidelines

Diagnostics ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 74
Author(s):  
Andrea Bernetti ◽  
Francesco Agostini ◽  
Alessandro de Sire ◽  
Massimiliano Mangone ◽  
Lucrezia Tognolo ◽  
...  
Keyword(s):  
Systematic Review ◽  
Neuropathic Pain ◽  
English Language ◽  
Pain Treatment ◽  
Rehabilitation Program ◽  
Pharmacological Intervention ◽  
Rehabilitative Treatment ◽  
Relevant Role ◽  
Rehabilitative Intervention ◽  
Somatosensory Nervous System

Background: Neuropathic pain is an injury or disease of the central and/or peripheral somatosensory nervous system, and it has a significant impact on quality of life, especially since it is often refractory to treatment. Rehabilitative intervention is considered in various guidelines on neuropathic pain treatment, although not in an organic nor detailed way. The aim of this systematic review was to analyze the most indicated therapeutic strategies, providing rehabilitative recommendations in the management of neuropathic pain. Methods: A systematic review was performed according to PRISMA guidelines. The scientific search, carried out until July 2020, considered guidelines in English language of the last thirteen years. Results: Six guidelines were analyzed, from which emerges that a multidisciplinary approach, comprehensive of pharmacologic and nonpharmacologic interventions, should drive neuropathic pain management. A relevant role in non-pharmacological intervention is played by rehabilitation, through an adequate tailored rehabilitation program and physical therapies. Conclusion: This analysis highlights the importance of rehabilitation but also the lack of evidence on various rehabilitative practices. Arises hence the need for further studies in this field to better define a rehabilitative treatment strategy.

Serotonergic System and Its Role in Epilepsy and Neuropathic Pain Treatment: A Review Based on Receptor Ligands

2015 ◽  
Vol 21 (13) ◽  
pp. 1723-1740 ◽  
Author(s):  
Katarzyna Panczyk ◽  
Sylwia Go.lda ◽  
Anna Waszkielewicz ◽  
Dorota Zelaszczyk ◽  
Agnieszka Gunia-Krzyz.ak ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Pain Treatment ◽  
Serotonergic System ◽  
Receptor Ligands

Sonographic Evaluation of Hidradenitis Suppurativa with Smartphone-Linked Portable Ultrasound

Dermatology ◽  
2021 ◽  
pp. 1-5
Author(s):  
Maximillian A. Weigelt ◽  
Yuval Hilerowicz ◽  
Jeffrey A. Leichter ◽  
Hadar Lev-Tov
Keyword(s):  
Hidradenitis Suppurativa ◽  
Wound Care ◽  
University Hospital ◽  
Clinical Staging ◽  
Routine Practice ◽  
Portable Ultrasound ◽  
Number Of Patients ◽  
Staging Systems ◽  
Conventional Ultrasound ◽  
Potential Benefits

Background: Clinical staging systems for hidradenitis suppurativa (HS) have poor interrater reliability and may underestimate disease activity. Sonographic staging systems may overcome these challenges, but conventional ultrasound (US) machines are expensive and bulky. Portable (p)US may facilitate the integration of sonography into routine practice. Objectives: To assess the ability of a novel smartphone-linked pUS device to identify key sonographic lesions of HS. Methods: The charts of 16 patients with HS who were assessed with pUS at the outpatient Dermatology and Wound Care Clinics of a university hospital center were retrospectively reviewed. Clinical and sonographic images of the affected areas were examined. The main outcome measures were the number of patients with identifiable sonographic lesions and the number of patients with subclinical lesions detected by pUS. Results: All 3 key sonographic lesions of HS were identifiable with pUS. Sonographic lesions were identified in 10 patients (62.5%). Subclinical lesions were identified in 2 patients (12.5%); in both cases, this affected management decisions. Conclusions: We demonstrate the ability of pUS to identify the key sonographic lesions of HS. pUS is a simple and affordable way to integrate HSUS into clinical and research settings, with clear potential benefits to patients.

Pain Intensity after Laseruvulopalatoplasty and Tonsillectomy

2003 ◽  
Vol 128 (2) ◽  
pp. 273-279 ◽  
Author(s):  
Hannu Kokki ◽  
Elina Nikanne ◽  
Mikko Aho ◽  
Jukka Virtaniemi
Keyword(s):  
Pain Relief ◽  
Pain Intensity ◽  
Pain Treatment ◽  
Antiinflammatory Drug ◽  
Nonsteroidal Antiinflammatory Drug ◽  
Free Access ◽  
Fentanyl Citrate ◽  
Rescue Analgesia ◽  
Parallel Group ◽  
At Home

OBJECTIVE: The first objective of this study was to evaluate pain intensity and opioid consumption during the first 24 hours after uvulopalatoplasty and tonsillectomy in the hospital, and the second was to evaluate pain intensity and its progression during the first 2 weeks after surgery at home. STUDY DESIGN AND SETTINGS: In a prospective parallel group study, 51 patients with uvulopalatoplasty or tonsillectomy were studied. Ketoprofen, a nonsteroidal antiinflammatory drug, and fentanyl citrate, an opioid, were used as analgesics. RESULTS: Despite ketoprofen infusion and free access to a patient-controlled pump with fentanyl citrate for rescue analgesia, inadequate pain relief was common both after uvulopalatoplasty (35%) and after tonsillectomy (28%) during the first 24 hours after surgery. The consumption of fentanyl citrate was similar after both operations. At home, pain intensity was highest in the mornings during the first 5 days, and 10 patients had some pain still after 2 weeks. Also at home, high pain scores were reported commonly in both groups. CONCLUSION: Sgnificant pain after uvulopalatoplasty and tonsillectomy lasted for several days. Ketoprofen in the commercial capsule form proved to be too short acting for overnight pain relief. SIGNIFICANCE: Pain treatment in patients with uvulopalatoplasty and tonsillectomy should be improved to allow patients a peaceful recovery after surgery.

Sign in / Sign up

Export Citation Format

Share Document